Association analysis of Tissue factor pathway inhibitor polymorphisms and haplotypes with Osteonecrosis of the femoral head in the Korean population

Molecules and Cells

Volumn 26, Issue 5, 2008, Pages 490-495

  Dai, Xue Lian ^a,b   Hong, Jung Min ^a   Oh, Bermseok ^c   Cho, Yoon Shin ^c   Lee, Jong Young ^c   Park, Eui Kyun ^a,d   Kim, Chang Yoon ^e   Kim, Shin Yoon ^a,b   Kim, Tae Ho ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Korea National Institute of Health   (South Korea)

^d Kyungpook National University   (South Korea)

^e Yeungnam University College of Medicine   (South Korea)

Author keywords

Femoral head; Osteonecrosis; Polymorphism; TFPI; Thrombosis

Indexed keywords

RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; BONE NECROSIS; CONTROLLED STUDY; EXON; FEMALE; FEMORAL HEAD OSTEONECROSIS; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION GENETICS; PROMOTER REGION; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; FEMUR HEAD NECROSIS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; KOREA; LINKAGE DISEQUILIBRIUM; LIPOPROTEINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 58049100393     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Abu-Shakra, M., Buskila, D., and Shoenfeld, Y. (2003). Osteonecrosis in patients with SLE. Clin. Rev. Allergy Immunol. 25, 13-24.
2. Aksoy, M.C., Aksoy, D.Y., Haznedaroglu, I.C., Sayinalp, N., Kirazli, S., and Alpaslan, M. (2005). Enhanced tissue factor pathway inhibitor response as a defense mechanism against ongoing local microvascular events of Legg-Calve-Perthes disease. Pediatr. Hematol. Oncol. 22, 391-399.
3. Ameziane, N., Seguin, C., Borgel, D., Fumeron, F., Moatti, D., Alhenc-Gelas, M., Grandchamp, B., Aiach, M., Emmerich, J., and de Prost, D. (2002). The -33T→C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb. Haemost. 88, 195-199.
4. Amini Nekoo, A., and Iles, D. (2008). Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter. Thromb. Res. 121, 813-819.
5. Amini-Nekoo, A., Futers, T.S., Moia, M., Mannucci, P.M., Grant, P.J., and Ariens, R.A. (2001). Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br. J. Haematol. 113, 537-543.
6. Assouline-Dayan, Y., Chang, C., Greenspan, A., Shoenfeld, Y., and Gershwin, M.E. (2002). Pathogenesis and natural history of osteonecrosis. Semin. Arthritis Rheum. 32, 94-124.
7. Atsumi, T., and Kuroki, Y. (1992). Role of impairment of blood supply of the femoral head in the pathogenesis of idiopathic osteonecrosis. Clin. Orthop. Relat. Res. 277, 22-30.
8. Bjorkman, A., Svensson, P.J., Hillarp, A., Burtscher, I.M., Runow, A., and Benoni, G. (2004). Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin. Orthop. Relat. Res. 425, 168-172.
9. Chang, J.D., Hur, M., Lee, S.S., Yoo, J.H., and Lee, K.M. (2008). Genetic background of nontraumatic osteonecrosis of the femoral head in the Korean population. Clin. Orthop. Relat. Res. 466, 1041-1046.
10. Cruess, R.L. (1986). Osteonecrosis of bone. Current concepts as to etiology and pathogenesis. Clin. Orthop. Relat. Res. 208, 30-39.
11. Fisher, D.E. (1978). The role of fat embolism in the etiology of corticosteroid- induced avascular necrosis: clinical and experimental results. Clin. Orthop. Relat. Res. 130, 68-80.
12. Girard, T.J., Warren, L.A., Novotny, W.F., Likert, K.M., Brown, S.G., Miletich, J.P., and Broze, G.J., Jr. (1989). Functional significance of the Kunitz-type inhibitory domains of lipoproteinassociated coagulation inhibitor. Nature 338, 518-520.
13. Girard, T.J., Eddy, R., Wesselschmidt, R.L., MacPhail, L.A., Likert, K.M., Byers, M.G., Shows, T.B., and Broze, G.J., Jr. (1991). Structure of the human lipoprotein-associated coagulation inhibitor gene. Intro/ exon gene organization and localization of the gene to chromosome 2. J. Biol. Chem. 266, 5036-5041.
14. Glueck, C.J., Glueck, H.I., Welch, M., Freiberg, R., Tracy, T., Hamer, T., and Stroop, D. (1994). Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb. Haemost. 71, 195-198.
15. Glueck, C.J., Freiberg, R., Glueck, H.I., Tracy, T., Stroop, D., and Wang, Y. (1995). Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am. J. Hematol. 48, 213-220.
16. Glueck, C.J., Brandt, G., Gruppo, R., Crawford, A., Roy, D., Tracy, T., Stroop, D., Wang, P., and Becker, A. (1997a). Resistance to activated protein C and Legg-Perthes disease. Clin. Orthop. Relat. Res. 338, 139-152.
17. Glueck, C.J., Freiberg, R., Tracy, T., Stroop, D., and Wang, P. (1997b). Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Clin. Orthop. Relat. Res. 334, 43-56.
18. Glueck, C.J., Fontaine, R.N., Gruppo, R., Stroop, D., Sieve-Smith, L., Tracy, T., and Wang, P. (1999). The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin. Orthop. Relat. Res. 366, 133-146.
19. Glueck, C.J., Freiberg, R.A., Fontaine, R.N., Tracy, T., and Wang, P. (2001). Hypofibrinolysis, thrombophilia, osteonecrosis. Clin. Orthop. Relat. Res. 366, 19-33.
20. Gruppo, R., Glueck, C.J., McMahon, R.E., Bouquot, J., Rabinovich, B.A., Becker, A., Tracy, T., and Wang, P. (1996). The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. J. Lab. Clin. Med. 127, 481-488.
21. Gruppo, R., Glueck, C.J., Wall, E., Roy, D., and Wang, P. (1998). Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J. Pediatr. 132, 885-888.
22. He, M., Wen, Z., He, X., Xiong, S., Liu, F., Xu, J., Li, J., Xie, Q., Jian, Z., Chen, F., et al. (2002). Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases. Thromb. Res. 107, 223-228.
23. Hirota, Y., Hirohata, T., Fukuda, K., Mori, M., Yanagawa, H., Ohno, Y., and Sugioka, Y. (1993). Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head. Am. J. Epidemiol. 137, 530-538.
24. Hong, J.M., Kim, T.H., Chae, S.C., Koo, K.H., Lee, Y.J., Park, E.K., Choi, J.Y., Ryoo, H. M., and Kim, S.Y. (2007). Association study of hypoxia inducible factor 1alpha (HIF1alpha) with osteonecrosis of femoral head in a Korean population. Osteoarthritis Cartilage 15, 688-694.
25. Jones, J.P., Jr. (1985). Fat embolism and osteonecrosis. Orthop. Clin. North Am. 16, 595-633.
26. Jones, J.P., Jr. (1999). Coagulopathies and osteonecrosis. Acta Orthop. Belg. 65, 5-8.
27. Jones, L.C., Mont, M.A., Le, T.B., Petri, M., Hungerford, D.S., Wang, P., and Glueck, C.J. (2003). Procoagulants and osteonecrosis. J. Rheumatol. 30, 783-791.
28. Kim, S.Y., Suh, J.S., Park, E.K., Jung, W.B., Kim, J.W., Koo, K.H., and Kim, C.Y. (2003). Factor V Leiden gene mutation in femoral head osteonecrosis. J. Korean Ortho. Res. Soc. 6, 259-264.
29. Kim, T.H., Hong, J.M., Park, E.K., and Kim, S.Y. (2007). Peroxisome proliferator-activated receptor-gamma gene polymorphisms are not associated with osteonecrosis of the femoral head in the Korean population. Mol. Cells 24, 388-393.
30. Lindahl, A.K. (1997). Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc. Res. 33, 286-291.
31. Lwaleed, B.A., and Bass, P.S. (2006). Tissue factor pathway inhibitor: structure, biology and involvement in disease. J. Pathol. 208, 327-339.
32. Miyanishi, K., Yamamoto, T., Irisa, T., Noguchi, Y., Sugioka, Y., and Iwamoto, Y. (1999). Increased level of apolipoprotein B/apolipoprotein A1 ratio as a potential risk for osteonecrosis. Ann. Rheum. Dis. 58, 514-516.
33. Miyata, T., Sakata, T., Kumeda, K., Uchida, K., Tsushima, M., Fujimura, H., Kawasaki, T., and Kato, H. (1998). C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb. Haemost. 80, 345-346.
34. Moatti, D., Seknadji, P., Galand, C., Poirier, O., Fumeron, F., Desprez, S., Garbarz, M., Dhermy, D., Arveiler, D., Evans, A., et al. (1999). Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler. Thromb. Vasc. Biol. 19, 862-869.
35. Moatti, D., Haidar, B., Fumeron, F., Gauci, L., Boudvillain, O., Seknadji, P., Olliver, V., Aumont, M.C., and de Prost, D. (2000). A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb. Haemost. 84, 244-249.
36. Mont, M.A., Ulrich, S.D., and Seyler, T.M. (2007). Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis. J. Rheumatol. 34, 466-468.
37. Nilsson, I.M., Krook, H., Sternby, N.H., Soderberg, E., and Soderstrom, N. (1961). Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Med. Scand. 169, 323-337.
38. Qin, Z.S., Niu, T., and Liu, J.S. (2002). Partition-ligation-expectation-maximization algorithm for haplotype inference with singlenucleotide polymorphisms. Am. J. Hum. Genet. 71, 1242-1247.
39. Rapaport, S.I., and Rao, L.V. (1995). The tissue factor pathway: how it has become a "prima ballerina". Thromb. Haemost. 74, 7-17.
40. Saito, S., Ohzono, K., and Ono, K. (1992). Early arteriopathy and postulated pathogenesis of osteonecrosis of the femoral head. The intracapital arterioles. Clin. Orthop. Relat. Res. 277, 98-110.
41. Van Veldhuizen, P.J., Neff, J., Murphey, M.D., Bodensteiner, D., and Skikne, B.S. (1993). Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am. J. Hematol. 44, 243-248.
42. Wang, Y., Li, Y., Mao, K., Li, J., Cui, Q., and Wang, G.J. (2003). Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis. Clin. Orthop. Relat. Res. 410, 213-224.
43. Wermes, C., Bergmann, F., Reller, B., and Sykora, K.W. (1999). Severe protein C deficiency and aseptic osteonecrosis of the hip joint: a case report. Eur. J. Pediatr. 158(Suppl. 3), S159-161.
44. Zalavras, C.G., Malizos, K.N., Dokou, E., and Vartholomatos, G. (2002). The 677C→T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head. Haematologica 87, 111-112.
45. Zalavras, C.G., Vartholomatos, G., Dokou, E., and Malizos, K.N. (2004). Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin. Orthop. Relat. Res. 422, 251-255.